相关实验视频
Updated: Jul 7, 2026
11:53
Cecal Ligation Puncture Procedure
Published on: May 7, 2011
54.6K
早期诺亚上腺素治疗败血性休克患者:更新的系统综述和分析,并进行试验顺序分析
Rui Shi1,2, Rayan Braïk2, Xavier Monnet2,3
1Department of Critical Care Medicine, The First Affiliated Hospital of Sun Yat-Sen University, The Emergency and Critical Care Clinical Research Center of Guangdong Province, Guangzhou, Guangdong, China.
Critical care (London, England)
|May 6, 2025
概括
在败血性休克中早期启动诺亚上腺素可显著降低死亡率并改善临床结果,包括减少液体输送和更快实现平均动脉压 (MAP) 目标. 需要进一步的随机对照试验 (RCT) 来证实这些发现.
科学领域:
- 临界护理医学 临界护理医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 对于在败血症休克中启动诺亚上腺素的最佳时间仍然是争论的主题.
- 这一系统性审查和元分析涉及早期与延迟的诺亚上腺素给药对患者结局的影响.
研究的目的:
- 评估早期启动诺拉上腺素对感染性休克成年患者死亡率和临床结果的影响.
- 综合来自随机对照试验 (RCT),倾向性得分匹配 (PSM) 和观察研究的证据.
主要方法:
- 在PubMed,EMbase和Cochrane图书馆系统搜索相关研究.
- 使用随机效应模型进行元分析和子组分析,以计算95%置信区间 (95%CI) 的几率比率 (OR) 和平均差异 (MD).
- 进行了试验顺序分析,以评估证据的确性.
主要成果:
- 在RCT (OR 0.49),聚合RCT和PSM (OR 0.65) 和观察性研究 (OR 0.71) 中,早期启动诺亚上腺素与降低死亡率有关.
- 亚组分析表明,当在1小时内开始服用诺阿基尼林,乳酸盐水平≤3毫摩尔/升时,死亡率降低.
- 二次结果有利于早期启动,显示6h减少液体体积 (MD -502 mL),更快地实现MAP目标 (MD -1.30h),以及更多的无机械通风日 (MD 3.99天).
结论:
- 在败血症休克中,早期的诺亚上腺素给药与改善的结果有关,包括较低的死亡率,减少的液体给药,以及更快的MAP正常化.
- 尽管结果很有希望,但试验序列分析表明,需要进一步的RCT来最终证实这些发现.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Acute Coronary Syndrome V: Nursing Management
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...